US loss of exclusivity · Neuroscience
Invega Sustenna
Johnson & Johnson
2031
US generics from
2025
Today: 2026
2037
2025 worldwide sales
$3.8B
Date basis
Patent-expiry estimate
US generics
Filed with the FDA
Pharma Patent Cliff
by readouts.io
Data checked 8 October 2026 ·
Full Invega Sustenna timeline →